You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK)中期歸母淨利19.21億元 同比減少77.3%
格隆匯 08-23 17:21

格隆匯8月23日丨中國生物製藥(01177.HK)發佈公吿,截至2022年6月30日止六個月,集團錄得收入約人民幣151.94億元,較去年同期增長約5.9%。歸屬於母公司持有者應占盈利約人民幣19.21億元,較去年同期減少約77.3%。每股盈利約人民幣10.30分,較去年同期減少約77.2%。扣除應占聯營公司及一家合營公司盈利及虧損(扣除相關税項及非控制權益),若干非現金項目及一次性調整後,經調整非《香港財務報吿準則》歸母淨利潤約人民幣16.58億元,較去年同期增長約4.5%。董事會宣佈派發中期股息每股6港仙。

報吿期內,新產品銷售收入佔集團總收入比例從去年約36.9%上升至該期間約43.5%。於該期間末,集團有計入流動資產的現金及銀行結餘約人民幣77.68億元、計入非流動資產的銀行存款約人民幣68.42億元,理財管理產品總額約人民幣76.35億元,資金儲備合共約人民幣222.46億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account